New Delhi: Bharat Biotech on Friday received approval from the Drugs Controller General of India (DCGI) to conduct its intranasal COVID-19 booster dose trials in India.
The trials are likely to be conducted at nine locations across the country, on 900 individuals.
The Subject Expert Committee (SEC) had earlier given in-principle approval for phase III booster dose study of Bharat Biotech’s intranasal COVID vaccine.
The Hyderabad-based pharmaceutical firm had proposed an intranasal booster dose for those who have been administered two doses of Covaxin or Covishield.
Prime Minister Narendra Modi had said last month that India will soon have an indigenous nasal COVID vaccine.
India launched a ‘precautionary’ third dose for frontline workers and senior citizens earlier this month.
Also Read: Intranasal COVID-19 Vaccine More Effective Than Traditional Counterparts
Comments are closed.